Crinetics Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Crinetics Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2017 to Q3 2024.
  • Crinetics Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $18.1M, a 64.2% increase year-over-year.
  • Crinetics Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $62.2M, a 66.8% increase year-over-year.
  • Crinetics Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $40.9M, a 44.8% increase from 2022.
  • Crinetics Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $28.3M, a 62.9% increase from 2021.
  • Crinetics Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $17.4M, a 66.4% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $62.2M $18.1M +$7.1M +64.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $55.1M $18.9M +$8.77M +86.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $46.3M $13.5M +$5.36M +66.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $40.9M $11.6M +$3.67M +46.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $37.3M $11M +$3.62M +48.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $33.7M $10.2M +$3.04M +42.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $30.6M $8.1M +$2.34M +40.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $28.3M $7.95M +$2.79M +54.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $25.5M $7.43M +$2.88M +63.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $22.6M $7.13M +$2.9M +68.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $19.7M $5.76M +$2.35M +69% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $17.4M $5.16M +$2.19M +73.7% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $15.2M $4.56M +$1.77M +63.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $13.4M $4.23M +$1.71M +67.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 $11.7M $3.41M +$1.26M +58.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $10.4M $2.97M +$1.14M +62.2% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $9.29M $2.78M +$928K +50.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 $8.36M $2.53M +$947K +59.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 $7.41M $2.15M +$1.12M +109% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $6.29M $1.83M +$983K +116% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-30
Q3 2019 $5.31M $1.85M +$1.08M +139% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $4.23M $1.58M +$1.31M +483% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 $2.92M $1.03M +$602K +141% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 $2.32M $848K Oct 1, 2018 Dec 31, 2018 10-K 2021-03-30
Q3 2018 $775K +$705K +1007% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $271K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 $426K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
Q3 2017 $70K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.